Matthew Burke on Potential Challenges Facing Nurses in the Field of Immunotherapy

Video

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses potential challenges nurses might face with the new advent on immunotherapy.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses potential challenges nurses might face with the new advent on immunotherapy.

Burke says immunotherapy is the beginning of a new paradigm in the treatment of cancer. In addition to learning about side effects associated with these agents, nurses are going to understand how to deal with combinations of immunotherapy agents.

Nurses will also be challenged to learn more about sequencing therapy, Burke says, which brings in a whole new class, and possible severity, of toxicity.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Related Content
Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

Lindsay Fischer
February 15th 2022
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

conceptual image of head and neck against yellow background

Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC

Spencer Feldman
September 11th 2024
Article

This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

Brielle Benyon
August 15th 2020
Podcast

Blood draws © adobe.stock.com

Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs

Megan Hollasch
June 7th 2023
Article

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Lindsay Fischer
June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.